SCHEMBL29696633

SCHEMBL29696633

CN(C)C(=O)[C@H](CC(=O)O)N(C)C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 4/20 0.49
▸ KMT2A Q03164 2/20 0.43
▸ FABP5 Q01469 3/20 0.43
▸ FABP7 O15540 2/20 0.43
▸ CYP1A2 P05177 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ PTGIR P43119 1/20 0.39
▸ EPHX2 P34913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24633569 1.00 CASP3 (0.49) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL30896052 1.00 CASP3 (0.49) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL24579191 1.00 CASP3 (0.49) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL23879119 1.00 CASP3 (0.49) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL29697687 1.00 CASP3 (0.49) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL24580371 0.92 CASP3 (0.43) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL29696710 0.92 CASP3 (0.43) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL26605926 0.92 CASP3 (0.43) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL24580368 0.92 CASP3 (0.43) CASP3KMT2AFABP5FABP7CYP1A2
SCHEMBL29416526 0.91 CASP3 (0.47) CASP3KMT2AFABP5FABP7CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678652-A1 METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-01-14 — — EP disclosed
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-17 — — US disclosed
US-12331072-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 — — US disclosed
US-20250188116-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-12 — — US disclosed
EP-4512818-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS Chugai Seiyaku Kabushiki Kaisha (JP) 2025-02-26 — — EP disclosed
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-13 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
EP-4467154-A1 MEDICINE FOR TREATING OR PREVENTING CANCER CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-11-27 — — EP disclosed
EP-4249496-A1 METHOD FOR SUPPORTING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-27 — — EP disclosed
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-09-21 — — US disclosed
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-22 — — US disclosed
CN-116615411-A Process for producing peptide compound containing N-substituted amino acid residue 中外制药株式会社 2023-08-18 — — CN disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
EP-4144747-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-03-08 — — EP disclosed
WO-2022234852-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2022-11-10 — — WO disclosed
EP-4043478-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-08-17 — — EP disclosed
WO-2022145444-A1 METHOD FOR SUPPORTING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS 中外製薬株式会社 2022-07-07 — — WO disclosed
WO-2022138891-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE 中外製薬株式会社 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS CASP3 3906/4885KMT2A 3145/4885FABP5 4094/4885
US-11732002-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound VIP, PEPD, MLN CASP3 1491/4885KMT2A 1449/4885FABP5 1921/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS CASP3 3906/4885KMT2A 3145/4885FABP5 4094/4885
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS CASP3 2833/4885KMT2A 1250/4885FABP5 4631/4885
US-12331072-B2 Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound VIP, PEPD, MLN CASP3 1491/4885KMT2A 1449/4885FABP5 1921/4885
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS CASP3 2833/4885KMT2A 1250/4885FABP5 4631/4885
US-20230295221-A1 EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES NGLY1, VIP, DNPEP CASP3 4334/4885KMT2A 3727/4885FABP5 2084/4885
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS CASP3 2833/4885KMT2A 1250/4885FABP5 4631/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS CASP3 3906/4885KMT2A 3145/4885FABP5 4094/4885
US-20250188116-A1 DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND VIP, PEPD, MLN CASP3 1491/4885KMT2A 1449/4885FABP5 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback